Current treatment of osteoporosis

Nallasivan, Subramanian

doi:10.4103/injr.injr_74_18

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The awareness of osteoporosis is low in India, with surveys indicating that only 10–15% of Indians are aware of the disease. [ 8 ] The availability of dual-energy X-ray absorptiometry (DXA) instruments, a key tool for diagnosing osteoporosis, is about 0.26 per million in India, far below the recommended number of 10.6 per million. [ 9 ] Indians fare poorly compared to other Asian countries such as Japan and Korea, where the availability of DXA is much higher (20.8 and 24.5 per million, respectively).…”

Section: G Aps In O Steoporosis C Are In I Ndiamentioning

confidence: 99%

APCO Framework of Clinical Standards of Care

Bhadada

Chandran

Pal

et al. 2021

Indian Journal of Endocrinology and Metabolism

View full text Add to dashboard Cite

Section: G Aps In O Steoporosis C Are In I Ndiamentioning

confidence: 99%

APCO Framework of Clinical Standards of Care

Bhadada

Chandran

Pal

et al. 2021

Indian Journal of Endocrinology and Metabolism

View full text Add to dashboard Cite

“…Various medications, such as bisphosphonates, hormone replacement therapy, estrogen agonists, calcitonin, parathyroid hormone (PTH), and denosumab, are utilized based on their affordability and availability. However, it is important to note that these drugs may also be associated with adverse effects [ 1 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

A Pilot, Open-Label, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Asthiposhak® Tablets in Participants Suffering From Asthikshaya or Osteopenia

Kumar¹,

Godatwar²,

Sharma³

et al. 2023

Cureus

View full text Add to dashboard Cite

Introduction Both osteoporosis and osteopenia are prevalent public health concerns worldwide and can lead to debilitating bone fractures. This study aimed to assess the efficacy of Asthiposhak® Tablets in individuals with Asthikshaya (osteopenia) by measuring changes in the bone mineral density (BMD) score before and after the intervention, specifically between visit 1 (baseline) and visit 8 (after 180 days of treatment). Methods The single-arm study involved the screening of participants for Asthikshaya (osteopenia) using baseline investigations, which included a bone mineral density (BMD) assessment through a dual-energy X-ray absorptiometry (DEXA) scan. A total of 36 participants were enrolled in the study, who took two Asthiposhak Tablets three times a day with lukewarm water, for a period of 180 days. Safety assessments, along with evaluations of BMD (DEXA Scan), Ayurvedic Symptom Score, and serum biochemical markers, were conducted through blood investigations. Efficacy and safety data were analyzed using 'intention-to-treat' analysis. Descriptive statistics were used to express data in percentages, mean ± SD, or median (IQR). Data at different intervals were compared using paired t-tests or Wilcoxon signed-rank tests. One-way analysis of variance (ANOVA) with Bonferroni correction tested the significance between visits for the Ayurvedic Symptom Score, and Friedman's two-way analysis of variance by ranks measured differences in vital parameters. The significance level used was p<0.05. Results Out of the initially recruited 36 participants, 30 successfully completed the study, consisting of 12 males and 18 females, with an age range of 40 to 70 years and a mean age of 51.33 years. After 180 days of treatment with Asthiposhak Tablets, a statistically significant (p<0.05) improvement in hip and spine BMD (T-score) was observed. Additionally, significant reductions in the mean Total Ayurvedic Symptom Score were noted at both 90 and 180 days of treatment compared to day 0. Moreover, the levels of bone-specific alkaline phosphatase and osteocalcin, serum bone markers, showed statistically significant (p<0.05) reduction after 180 days of treatment compared to day 0. Importantly, all safety variables, including laboratory investigations, remained within the normal range following the 180-day treatment with Asthiposhak Tablets. Conclusion Asthiposhak Tablets exhibited significant efficacy in enhancing both BMD (T-score) and Ayurvedic Symptom Score, thereby substantiating their osteoprotective potential in individuals with Asthikshaya (osteopenia). Furthermore, the tablets were found to reduce the levels of biochemical markers, such as serum bone-specific alkaline phosphatase and osteocalcin, suggesting their anti-resorptive action.

show abstract

“…The major advantages of using this technique is that it is non-invasive, patient friendly, has low radiation exposure, and high precision. [ 8 ]…”

Section: Introductionmentioning

confidence: 99%

Prevalence and predictors of low bone mineral density among adults aged 50 years and above in Chandigarh, India

Kalia

Chaturvedi

Rohilla

et al. 2022

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

Background: Osteoporosis, defined as skeletal disorder characterized by reduced bone density and strength, is prevalent in both developing and developed countries. Dual energy X-ray absorptiometry (DEXA) is an effective tool to diagnose low bone mineral density (BMD). Objective: This study objective was to know the prevalence and predictors of low BMD in a community-based screening program among the adult population using DEXA scan. Methods: In this community-based study conducted between January and June 2016, a population-based screening program was offered to both males and females of age 50 years and above. BMD was measured to derive T-scores and classify as normal, osteopenic, and osteoporotic individuals. Results: A total of 455 subjects were enrolled where 62.4% proportion was women; 42.6% subjects were in the age group of 50 to 59 years. The prevalence of osteoporosis and osteopenia was 20.9% and 48.1%, respectively. Hypertension (23.7%) and diabetes (8.4%) were common comorbidities. Age and gender (female) were independent predictors of low BMD. Conclusion: Osteoporosis/osteopenia is present in both genders with increasing trend with age advancement. Institution of timely screening will prevent the morbidity associated with fractures due to low BMD.

show abstract

Current treatment of osteoporosis

Cited by 6 publications

References 0 publications

APCO Framework of Clinical Standards of Care

APCO Framework of Clinical Standards of Care

A Pilot, Open-Label, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Asthiposhak® Tablets in Participants Suffering From Asthikshaya or Osteopenia

Prevalence and predictors of low bone mineral density among adults aged 50 years and above in Chandigarh, India

Contact Info

Product

Resources

About